The FDA has accepted a BLA under its accelerated approval pathway from uniQure for ifezuntirgene inilparvovec to treat Huntington’s disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results